Tyrosine Protein Kinase Mer - Drugs In Development, 2021
Tyrosine Protein Kinase Mer - Drugs In Development, 2021
SUMMARY
According to the recently published report 'Tyrosine Protein Kinase Mer - Drugs In Development, 2021'; Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) pipeline Target constitutes close to 19 molecules. Out of which approximately 17 molecules are developed by companies and remaining by the universities/institutes.
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Proto-oncogene tyrosine-protein kinase MER is an enzyme encoded by the MERTK gene. It regulates many physiological processes including cell survival, migration, differentiation, and phagocytosis of apoptotic cells. It plays a role in various processes such as macrophage clearance of apoptotic cells, platelet aggregation, cytoskeleton reorganization and engulfment. Functions in the retinal pigment epithelium (RPE) as a regulator of rod outer segments fragments phagocytosis. It also plays an important role in inhibition of Toll-like receptors (TLRs)-mediated innate immune response by activating STAT1.
The report 'Tyrosine Protein Kinase Mer - Drugs In Development, 2021' outlays comprehensive information on the Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 4, 9 and 1 respectively. Similarly, the universities portfolio in Phase I and Preclinical stages comprises 1 and 1 molecules, respectively.
Report covers products from therapy areas Oncology and Ophthalmology which include indications Non-Small Cell Lung Cancer, Solid Tumor, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Gastric Cancer, Triple-Negative Breast Cancer (TNBC), Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Bile Duct Cancer (Cholangiocarcinoma), Breast Cancer, Gallbladder Cancer, Glioblastoma Multiforme (GBM), Lung Cancer, Melanoma, Metastatic Hepatocellular Carcinoma (HCC), Metastatic Melanoma, Ovarian Cancer, Renal Cell Carcinoma, Soft Tissue Sarcoma, Adenocarcinoma Of The Gastroesophageal Junction, Bladder Cancer, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Colon Cancer, Colorectal Cancer, Epithelial Ovarian Cancer, Gastroesophageal (GE) Junction Carcinomas, Head And Neck Cancer Squamous Cell Carcinoma, Hematological Tumor, Hepatocellular Carcinoma, Kidney Cancer (Renal Cell Cancer), Liposarcoma, Mantle Cell Lymphoma, Metastatic Biliary Tract Cancer, Metastatic Colorectal Cancer, Metastatic Transitional (Urothelial) Tract Cancer, Myelodysplastic Syndrome, Non-Hodgkin Lymphoma, Oral Cavity (Mouth) Cancer, Peripheral Nerve Sheath Tumor (Neurofibrosarcoma), Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Retinitis Pigmentosa (Retinitis), Rhabdomyosarcoma, Squamous Non-Small Cell Lung Cancer, Synovial Sarcoma and Transitional Cell Carcinoma (Urothelial Cell Carcinoma).
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
According to the recently published report 'Tyrosine Protein Kinase Mer - Drugs In Development, 2021'; Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) pipeline Target constitutes close to 19 molecules. Out of which approximately 17 molecules are developed by companies and remaining by the universities/institutes.
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Proto-oncogene tyrosine-protein kinase MER is an enzyme encoded by the MERTK gene. It regulates many physiological processes including cell survival, migration, differentiation, and phagocytosis of apoptotic cells. It plays a role in various processes such as macrophage clearance of apoptotic cells, platelet aggregation, cytoskeleton reorganization and engulfment. Functions in the retinal pigment epithelium (RPE) as a regulator of rod outer segments fragments phagocytosis. It also plays an important role in inhibition of Toll-like receptors (TLRs)-mediated innate immune response by activating STAT1.
The report 'Tyrosine Protein Kinase Mer - Drugs In Development, 2021' outlays comprehensive information on the Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 4, 9 and 1 respectively. Similarly, the universities portfolio in Phase I and Preclinical stages comprises 1 and 1 molecules, respectively.
Report covers products from therapy areas Oncology and Ophthalmology which include indications Non-Small Cell Lung Cancer, Solid Tumor, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Gastric Cancer, Triple-Negative Breast Cancer (TNBC), Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Bile Duct Cancer (Cholangiocarcinoma), Breast Cancer, Gallbladder Cancer, Glioblastoma Multiforme (GBM), Lung Cancer, Melanoma, Metastatic Hepatocellular Carcinoma (HCC), Metastatic Melanoma, Ovarian Cancer, Renal Cell Carcinoma, Soft Tissue Sarcoma, Adenocarcinoma Of The Gastroesophageal Junction, Bladder Cancer, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Colon Cancer, Colorectal Cancer, Epithelial Ovarian Cancer, Gastroesophageal (GE) Junction Carcinomas, Head And Neck Cancer Squamous Cell Carcinoma, Hematological Tumor, Hepatocellular Carcinoma, Kidney Cancer (Renal Cell Cancer), Liposarcoma, Mantle Cell Lymphoma, Metastatic Biliary Tract Cancer, Metastatic Colorectal Cancer, Metastatic Transitional (Urothelial) Tract Cancer, Myelodysplastic Syndrome, Non-Hodgkin Lymphoma, Oral Cavity (Mouth) Cancer, Peripheral Nerve Sheath Tumor (Neurofibrosarcoma), Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Retinitis Pigmentosa (Retinitis), Rhabdomyosarcoma, Squamous Non-Small Cell Lung Cancer, Synovial Sarcoma and Transitional Cell Carcinoma (Urothelial Cell Carcinoma).
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1)
- The report reviews Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Overview
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Companies Involved in Therapeutics Development
Celldex Therapeutics Inc
Celon Pharma SA
Dong-A Socio Holdings Co Ltd
Eli Lilly and Co
F. Hoffmann-La Roche Ltd
HEC Pharma Co Ltd
Hope Biosciences Inc
Incyte Corp
Mediolanum farmaceutici SpA
Meryx Inc
Mirati Therapeutics Inc
Ono Pharmaceutical Co Ltd
Pfizer Inc
Qurient Co Ltd
Rgenix Inc
SignalChem Lifesciences Corp
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Drug Profiles
CDX-0168 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CT-413 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DA-4501 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ELB-031 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate MERTK for Retinitis Pigmentosa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HOPE-777 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INCB-81776 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Mer-590 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
merestinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MRX-2843 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MRX-6313 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ONO-7475 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PF-07265807 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Q-702 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RGX-019 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RXDX-106 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sitravatinib malate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Mer Tyrosine Kinase for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit MERTK for Hematological and Solid Tumors - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Dormant Products
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Discontinued Products
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Product Development Milestones
Featured News & Press Releases
Apr 11, 2021: BeiGene presents clinical data on Sitravatinib in combination with Tislelizumab at the AACR Annual Meeting 2021
Mar 10, 2021: BeiGene announces presentation of clinical data on Sitravatinib in combination with tislelizumab at the AACR Annual Meeting 2021
Jan 26, 2021: Qurient enrolls first patient in Q702 U.S. phase 1 study
Sep 18, 2020: Mirati Therapeutics presents phase 2 data on sitravatinib in combination with nivolumab in urothelial cancer At ESMO Virtual Congress
Jun 22, 2020: RGENIX presents results from preclinical safety and efficacy studies of RGX-019 at the 2020 AACR Annual Meeting
May 26, 2020: Qurient announces U.S. FDA clearance of IND application for Q702, a novel cancer immunotherapy
Feb 15, 2020: Mirati Therapeutics announces initial data in Renal Cell Carcinoma from ongoing investigator sponsored clinical trial Of Sitravatinib in combination With Nivolumab at The 2020 ASCO Genitourinary Cancers Syposium
Dec 13, 2019: Sitravatinib plus Tislelizumab show promise in platinum-resistant advanced ovarian cancer
Nov 09, 2019: Mirati Therapeutics Presents Data From Ongoing Clinical Trials Of Sitravatinib In Combination With Nivolumab At The SITC 34th Annual Meeting
Oct 23, 2019: Mirati Therapeutics announces presentation of interim phase 2 Sitravatinib data In Urothelial Carcinoma and Oral Cavity Squamous Cell Carcinoma At The SITC 34th Annual Meeting
Apr 08, 2019: Dong-A ST's investigational drug posts positive study results
Apr 03, 2019: Rgenix presents pre-clinical data on RGX-019 at the 2019 AACR Annual Meeting
Apr 01, 2019: Rgenix to present abstract on RGX-019 at the 2019 AACR Annual Meeting
Nov 23, 2018: Mirati Therapeutics joins Cancer Research UK’s Stratified Medicine Programme
Nov 10, 2018: Celldex presents emerging MerTK antibody program at the Society for Immunotherapy of Cancer's 33rd annual meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Overview
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Companies Involved in Therapeutics Development
Celldex Therapeutics Inc
Celon Pharma SA
Dong-A Socio Holdings Co Ltd
Eli Lilly and Co
F. Hoffmann-La Roche Ltd
HEC Pharma Co Ltd
Hope Biosciences Inc
Incyte Corp
Mediolanum farmaceutici SpA
Meryx Inc
Mirati Therapeutics Inc
Ono Pharmaceutical Co Ltd
Pfizer Inc
Qurient Co Ltd
Rgenix Inc
SignalChem Lifesciences Corp
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Drug Profiles
CDX-0168 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CT-413 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DA-4501 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ELB-031 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate MERTK for Retinitis Pigmentosa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HOPE-777 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INCB-81776 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Mer-590 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
merestinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MRX-2843 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MRX-6313 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ONO-7475 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PF-07265807 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Q-702 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RGX-019 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RXDX-106 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sitravatinib malate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Mer Tyrosine Kinase for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit MERTK for Hematological and Solid Tumors - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Dormant Products
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Discontinued Products
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Product Development Milestones
Featured News & Press Releases
Apr 11, 2021: BeiGene presents clinical data on Sitravatinib in combination with Tislelizumab at the AACR Annual Meeting 2021
Mar 10, 2021: BeiGene announces presentation of clinical data on Sitravatinib in combination with tislelizumab at the AACR Annual Meeting 2021
Jan 26, 2021: Qurient enrolls first patient in Q702 U.S. phase 1 study
Sep 18, 2020: Mirati Therapeutics presents phase 2 data on sitravatinib in combination with nivolumab in urothelial cancer At ESMO Virtual Congress
Jun 22, 2020: RGENIX presents results from preclinical safety and efficacy studies of RGX-019 at the 2020 AACR Annual Meeting
May 26, 2020: Qurient announces U.S. FDA clearance of IND application for Q702, a novel cancer immunotherapy
Feb 15, 2020: Mirati Therapeutics announces initial data in Renal Cell Carcinoma from ongoing investigator sponsored clinical trial Of Sitravatinib in combination With Nivolumab at The 2020 ASCO Genitourinary Cancers Syposium
Dec 13, 2019: Sitravatinib plus Tislelizumab show promise in platinum-resistant advanced ovarian cancer
Nov 09, 2019: Mirati Therapeutics Presents Data From Ongoing Clinical Trials Of Sitravatinib In Combination With Nivolumab At The SITC 34th Annual Meeting
Oct 23, 2019: Mirati Therapeutics announces presentation of interim phase 2 Sitravatinib data In Urothelial Carcinoma and Oral Cavity Squamous Cell Carcinoma At The SITC 34th Annual Meeting
Apr 08, 2019: Dong-A ST's investigational drug posts positive study results
Apr 03, 2019: Rgenix presents pre-clinical data on RGX-019 at the 2019 AACR Annual Meeting
Apr 01, 2019: Rgenix to present abstract on RGX-019 at the 2019 AACR Annual Meeting
Nov 23, 2018: Mirati Therapeutics joins Cancer Research UK’s Stratified Medicine Programme
Nov 10, 2018: Celldex presents emerging MerTK antibody program at the Society for Immunotherapy of Cancer's 33rd annual meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Indications, 2021
Number of Products under Development by Indications, 2021 (Contd..1)
Number of Products under Development by Indications, 2021 (Contd..2)
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Products under Development by Companies, 2021 (Contd..2)
Products under Development by Companies, 2021 (Contd..3)
Products under Development by Companies, 2021 (Contd..4)
Number of Products under Investigation by Universities/Institutes, 2021
Products under Investigation by Universities/Institutes, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Pipeline by Celldex Therapeutics Inc, 2021
Pipeline by Celon Pharma SA, 2021
Pipeline by Dong-A Socio Holdings Co Ltd, 2021
Pipeline by Eli Lilly and Co, 2021
Pipeline by F. Hoffmann-La Roche Ltd, 2021
Pipeline by HEC Pharma Co Ltd, 2021
Pipeline by Hope Biosciences Inc, 2021
Pipeline by Incyte Corp, 2021
Pipeline by Mediolanum farmaceutici SpA, 2021
Pipeline by Meryx Inc, 2021
Pipeline by Mirati Therapeutics Inc, 2021
Pipeline by Ono Pharmaceutical Co Ltd, 2021
Pipeline by Pfizer Inc, 2021
Pipeline by Qurient Co Ltd, 2021
Pipeline by Rgenix Inc, 2021
Pipeline by SignalChem Lifesciences Corp, 2021
Dormant Products, 2021
Dormant Products, 2021 (Contd..1)
Discontinued Products, 2021
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Indications, 2021
Number of Products under Development by Indications, 2021 (Contd..1)
Number of Products under Development by Indications, 2021 (Contd..2)
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Products under Development by Companies, 2021 (Contd..2)
Products under Development by Companies, 2021 (Contd..3)
Products under Development by Companies, 2021 (Contd..4)
Number of Products under Investigation by Universities/Institutes, 2021
Products under Investigation by Universities/Institutes, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Pipeline by Celldex Therapeutics Inc, 2021
Pipeline by Celon Pharma SA, 2021
Pipeline by Dong-A Socio Holdings Co Ltd, 2021
Pipeline by Eli Lilly and Co, 2021
Pipeline by F. Hoffmann-La Roche Ltd, 2021
Pipeline by HEC Pharma Co Ltd, 2021
Pipeline by Hope Biosciences Inc, 2021
Pipeline by Incyte Corp, 2021
Pipeline by Mediolanum farmaceutici SpA, 2021
Pipeline by Meryx Inc, 2021
Pipeline by Mirati Therapeutics Inc, 2021
Pipeline by Ono Pharmaceutical Co Ltd, 2021
Pipeline by Pfizer Inc, 2021
Pipeline by Qurient Co Ltd, 2021
Pipeline by Rgenix Inc, 2021
Pipeline by SignalChem Lifesciences Corp, 2021
Dormant Products, 2021
Dormant Products, 2021 (Contd..1)
Discontinued Products, 2021
LIST OF FIGURES
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Top 10 Indications, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Top 10 Indications, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021
